These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10623378)

  • 1. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.
    Nichol KL; Goodman M
    Pharmacoeconomics; 1999; 16 Suppl 1():63-71. PubMed ID: 10623378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of influenza vaccine in the elderly.
    Nichol KL; Margolis KL; Wouremna J; von Sternberg T
    Gerontology; 1996; 42(5):274-9. PubMed ID: 8940650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
    Nichol KL; Margolis KL; Wuorenma J; Von Sternberg T
    N Engl J Med; 1994 Sep; 331(12):778-84. PubMed ID: 8065407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years.
    Nichol KL; Goodman M
    Vaccine; 2002 May; 20 Suppl 2():S21-4. PubMed ID: 12110251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
    Nichol KL; Baken L; Nelson A
    Ann Intern Med; 1999 Mar; 130(5):397-403. PubMed ID: 10068413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.
    Mullooly JP; Bennett MD; Hornbrook MC; Barker WH; Williams WW; Patriarca PA; Rhodes PH
    Ann Intern Med; 1994 Dec; 121(12):947-52. PubMed ID: 7978721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    Nichol KL
    Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Health economic impact of viral respiratory infections and pneumonia diseases on the elderly population in Poland].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2010 Jul; 29(169):37-40. PubMed ID: 20712246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.
    Nichol KL; Wuorenma J; von Sternberg T
    Arch Intern Med; 1998 Sep; 158(16):1769-76. PubMed ID: 9738606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.
    Nichol KL; Baken L; Wuorenma J; Nelson A
    Arch Intern Med; 1999 Nov; 159(20):2437-42. PubMed ID: 10665892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.
    Nichol KL; Nordin J; Mullooly J; Lask R; Fillbrandt K; Iwane M
    N Engl J Med; 2003 Apr; 348(14):1322-32. PubMed ID: 12672859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of influenza vaccination. Assessment for The Netherlands.
    Postma MJ; Bos JM; van Gennep M; Jager JC; Baltussen R; Sprenger MJ
    Pharmacoeconomics; 1999; 16 Suppl 1():33-40. PubMed ID: 10623374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential cost savings attributable to influenza vaccination of school-aged children.
    White T; Lavoie S; Nettleman MD
    Pediatrics; 1999 Jun; 103(6):e73. PubMed ID: 10353970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations.
    Hak E; Nordin J; Wei F; Mullooly J; Poblete S; Strikas R; Nichol KL
    Clin Infect Dis; 2002 Aug; 35(4):370-7. PubMed ID: 12145718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study.
    Pisu M; Meltzer MI; Hurwitz ES; Haber M
    Pharmacoeconomics; 2005; 23(1):55-67. PubMed ID: 15693728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of influenza and benefits of vaccination.
    Nichol KL
    Vaccine; 1999 Jul; 17 Suppl 1():S47-52. PubMed ID: 10471180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons.
    Nichol KL; Nordin J; Mullooly J
    Vaccine; 2006 Mar; 24(10):1562-8. PubMed ID: 16300868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.